Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

Author(s):

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

EP: 1.Overview of Hepatocellular Carcinoma (HCC)

EP: 2.Diagnosing Patients With Hepatocellular Carcinoma

EP: 3.Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

EP: 4.Treatment Approaches for Patients With Early-Stage HCC

EP: 5.The Role of Adjuvant Therapy in Patients With Early-Stage HCC

EP: 6.Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

EP: 7.Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

EP: 8.Optimal Sequencing in Patients With Advanced HCC

EP: 9.Safety Profiles of Available Therapies in Advanced HCC

EP: 10.The Future of HCC Treatment

EP: 11.First-Line Systemic Treatment Options for Patients With Advanced HCC

Now Viewing

EP: 12.Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

EP: 13.Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

EP: 14.The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

EP: 15.Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

EP: 16.Future of Advanced HCC Treatment

Latest Conference Coverage

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512